Viasys retains banker to divest monitoring unit
This article was originally published in Clinica
Viasys Healthcare of Conshohocken, Pennsylvania, has appointed investment bank The Nassau Group to advise it on the sale of its wireless patient monitoring systems unit, Medical Data Electronics (MDE). The company says it wants to focus on respiratory, neurocare and medical/surgical products. As a result, it will book a pre-tax charge of about $15m in the third quarter.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.